Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Détails

ID Serval
serval:BIB_9EFEC1A3C1D2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
Périodique
Blood
Auteur⸱e⸱s
Iqbal J., Wright G., Wang C., Rosenwald A., Gascoyne R.D., Weisenburger D.D., Greiner T.C., Smith L., Guo S., Wilcox R.A., Teh B.T., Lim S.T., Tan S.Y., Rimsza L.M., Jaffe E.S., Campo E., Martinez A., Delabie J., Braziel R.M., Cook J.R., Tubbs R.R., Ott G., Geissinger E., Gaulard P., Piccaluga P.P., Pileri S.A., Au W.Y., Nakamura S., Seto M., Berger F., de Leval L., Connors J.M., Armitage J., Vose J., Chan W.C., Staudt L.M., Lymphoma Leukemia Molecular Profiling Project, the International Peripheral T-cell Lymphoma Project
Contributeur⸱rice⸱s
Lymphoma Leukemia Molecular Profiling Project, the International Peripheral T-cell Lymphoma Project
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
123
Numéro
19
Pages
2915-2923
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS). Gene-expression profiles on 372 PTCL cases were analyzed and robust molecular classifiers and oncogenic pathways that reflect the pathobiology of tumor cells and their microenvironment were identified for major PTCL-entities, including 114 angioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separated into NK-cell and gdT-cell lymphomas. Thirty-seven percent of morphologically diagnosed PTCL-NOS cases were reclassified into other specific subtypes by molecular signatures. Reexamination, immunohistochemistry, and IDH2 mutation analysis in reclassified cases supported the validity of the reclassification. Two major molecular subgroups can be identified in the remaining PTCL-NOS cases characterized by high expression of either GATA3 (33%; 40/121) or TBX21 (49%; 59/121). The GATA3 subgroup was significantly associated with poor overall survival (P = .01). High expression of cytotoxic gene-signature within the TBX21 subgroup also showed poor clinical outcome (P = .05). In AITL, high expression of several signatures associated with the tumor microenvironment was significantly associated with outcome. A combined prognostic score was predictive of survival in an independent cohort (P = .004).
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/03/2014 15:41
Dernière modification de la notice
20/08/2019 15:05
Données d'usage